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a  b  s  t  r  a  c  t
Background:  Photosensitizer  formation  and  epidermal  penetration  depth  represent  basic  predictors  of
drug  efﬁcacy  in dermatological  Photodynamic  Therapy  (PDT).  Different  drug  formulations  and  application
standards  are  used  to perform  PDT  in clinical  practice.
Methods:  Thus,  we developed  a human  ex vivo  model  suitable  to  explore  drug  permeation  in human  skin
and  compared  in  10  patients  the  penetration  of  nanoemulsion  formulation  (BF-200  ALA)  with  that  of a
20%  ALA  cream  formulation  frequently  used  in clinical  practice.  Protoporphyrin  IX  (PpIX) formation  was
assessed  according  to  different  durations  of incubation  with  both  preparations.
Results:  BF-200  ALA  led  to more  intense  PpIX  ﬂuorescence  than  the  20%  ALA  cream  formulation  as  assessed
by ﬂuorescence  microscopy:  after 12  h  of incubation,  total  measured  ﬂuorescence  was  at  101,995  ﬂuores-
cence units  with  BF-200  ALA  and  40,960  ﬂuorescence  units  with  20%  ALA  cream, respectively.  This  could
be  reproduced  using  quantitative  ﬂuorimetric  measurements  in  tissue  lysates.  After  the clinically  relevant
incubation  time  of  3 h the  PpIX  concentration  induced  by BF-200  ALA  was  more  than  three-fold  higher
than  that induced  by  the  20%  ALA  formulation  (7.1  ± 5.5 and  1.9  ±  1.8  nmol/l,  p  < 0.05, Mann–Whitney
U-test)  and  four-fold  higher  after 12 h (30.0  ±  4.6  and  6.7 ±  2.0 nmol/l,  p < 0.01,  Mann–Whitney  U-test).
Conclusions:  In spite  of  the  50%  lower  ALA  content  BF-200  ALA  triggers  signiﬁcantly  higher  PpIX  concen-
trations  than the  20%  ALA  formulation,  indicating  that clinical  efﬁcacy  with  BF-200  ALA  may  be higher.
Moreover,  the  ex vivo  eyelid  skin  model  may  represent  a useful  tool  to investigate  drug  permeation  in
human skin.
©  2015  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. Introduction
The efﬁcacy of 5-aminolevulinic acid (ALA) Photodynamic Ther-
py (PDT) for epidermal neoplasias is associated with effective
ormation and distribution of the photosensitizer protoporphyrin
X (PpIX). To remove epidermal cancers the sensitizer should reach
he proliferative basal layer and remove the neoplastic cells located
here [1,2]. Both commonly used compounds that drive epidermal
pIX formation (aminolevulinic acid and its methyl ester) are not
ufﬁciently lipophilic to pass through the lipid membranes with-
ut speciﬁc transporters [3]. While the ALA-methyl-ester (MAL) is
lightly more stable in an aqueous environment [4], it is less potent
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in forming PpIX [5]. Fritsch et al. suggested MAL  to display a higher
tumor cell selectivity than ALA [6]. However, more recent publi-
cations by Novak et al. and Schulten et al. hold evidence for the
opposite [5,7]. Despite its advantageous pharmacological proﬁle,
the use of ALA has long been hampered by its instability in aque-
ous environments. Emulsions of lipid vesicles with nanometre sizes
are known to enhance compound stability and penetration into
the epidermis [8]. It is highly conceivable that preclinical analysis
of epidermal PpIX formation may  readily predict clinical efﬁcacy.
Nevertheless, penetration of different ALA and MAL formations has
been determined in porcine skin [9,10] which in structure resem-
bles human facial skin [11] but differs in thickness of the vital
epidermis and stratum corneum [12,13]. This difference may  ham-
per translation to the clinical situation [14]. Other authors assessed
epidermal PpIX formation in murine skin [15], healthy human skin
[16] or human basal cell carcinoma [17]. While the ﬁrst is of lim-
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ted predictive value due to the differences between human and
urine skin, the latter are clinically more relevant, but have other
imitations. Using healthy volunteers’ skin after photosensitizer
pplication in vivo limits the number of samples that can possibly
e obtained and usually shifts the application site from the face to
ther parts of the body. Assessing PpIX formation in pretreated and
ubsequently excised tumors (e.g. BCC as in Ref. [17]) is a very rel-
vant approach but limited by the availability of suitable patients.
pper eyelid surgery is a routine intervention in dermatological
ractice. It yields healthy facial skin that closely resembles the loca-
ions where PDT is performed for actinic keratosis and may  thus be
uitable for in vitro analysis of PpIX formation in human epidermis.
PpIX formation and distribution were observed microscopically
n slices and quantitatively determined in tissue lysates of the same
pecimen. Using this approach we compared PpIX formation after
he application of a nanoscale lipid vesicle formulation containing
LA (BF-200 ALA) and a compounded formulation containing 20%
LA frequently used in clinical practice. We  found that PpIX for-
ation after application of BF-200 ALA was more rapid and more
bundant than with the 20% ALA formulation.
. Material and methods
.1. Chemicals
BF-200 ALA, a nanoscale lipid vesicle gel formulation contain-
ng 78 mg/g ALA (free base, corresponding to 10% ALA-HCl) was
btained from Biofrontera Pharma GmbH. Placebo was  the same gel
ithout active ingredient. A 20% (w/w) ALA cream as routinely used
n clinical practice was prepared by mixing the hydrophilic non-
onic cream NRF (Bombastus Werke AG, Freital, Germany) and ALA
Biofrontera Bioscience GmbH). 20% ALA cream was freshly pre-
ared for every experimental day. All other chemicals and reagents
ere purchased from Sigma–Aldrich (Taufkirchen, Germany) or
hermo Fisher Scientiﬁc (Waltham, MA,  USA).
.2. Human skin and surgery
Human upper eyelid skin was obtained from ten routine
lepharoplastic surgeries performed in one dermatological cen-
er. Informed consent was collected from all of the included
atients. The experiments were approved by the local ethical com-
ittee (Ethical committee: University Witten-Herdecke; number
3/2012). Eyelid material was comprised of either one (2 of 10
atients) or both (8 of 10 patients) upper lids (see Table 1) and was
ubjected to experimental processes immediately. Surgical proce-
ure was carried out as follows: the incision lines were marked with
ots, then local anaesthesia (Scandicain® with epinephrine) was
nﬁltrated subcutaneously. The excision boundaries were put under
ension and incisions were made with a number 15 blade starting at
he medial lower boundary, followed by the medial upper bound-
ry. Then, using surgical tweezers, the lateral part of the strip of skin
as pulled upward and dissected. Hemostasis was performed by an
lectrocoagulation forceps. Finally, the wound was closed using a
.0 Prolene® R intracutaneous suture (see Fig. 1A,B)
.3. Test system
Eyelid skin was superﬁcially disinfected and degreased using
0% ethanol. Test items BF-200 ALA, placebo gel or 20% 5-ALA for-
ulation were topically applied to the epidermis at approximately
 mm thickness. Test items were allowed to dry for 10 min  and
 mm punch biopsies were performed. Biopsies were immediately
ransferred to a culture chamber (Fig. 1). Culture chambers (see
ig. 1C) were built using a six well cell culture plate and inserts with
.4 m pore PET microporous membrane, into which holes of 3 mmdynamic Therapy 14 (2016) 40–46 41
diameter were punched. Tissue biopsies were placed onto these
holes with the epidermal side upwards and inserts were transferred
to the wells containing DMEM/F12 medium without phenol red
(Invitrogen). The dermis had contact to the medium while the epi-
dermis was  exposed to air. Ex vivo cultures were incubated at 37 ◦C
and 5% CO2 in a humidiﬁed atmosphere. After incubation times of
0, 1, 3, 5 and 12 h, samples were immersed in Tissue Tek freezing
medium (Jung, Germany) and frozen in isopentane on dry ice, using
Tissue Tek Cryomolds (1 × 1 × 0.5 cm).
2.4. Cryosectioning and processing of sections
Cryo slices were cut using a cryotome (Leica, Wetzlar, Germany)
at a thickness of 20 m.  Care was  taken to avoid exposure to intense
light. One slice was  ﬁxed in 4% formaldehyde and stained with
hematoxylin and eosin (H&E) according to standard methods, while
a neighboring slice was  microscopically analyzed for PpIX ﬂuores-
cence using a set up as previously described [10].
2.5. Fluorescence microscopy
For PpIX distribution analysis relative to epidermal depth, a
plot proﬁle approach was chosen. 16 bit grayscale images (400 nm
excitation, 600 nm emission ﬁlters, 200-fold magniﬁcation, 750 ms
exposure time using a PCO. 1400-m-FW-CM camera, PCO AG, Kel-
heim, Germany on an Axioskop 2, Zeiss, Jena, Germany) were
taken. In an initial calibration step before the experimental series,
PpIX solutions of nanomolar concentrations (1, 10, 100 nmol/l) and
untreated tissue slices were used as standards for ﬂuorescence
signals and tissue auto ﬂuorescence, respectively, to establish the
microscope and illumination settings used in this study. Exposure
time was kept constant at 750 ms  throughout all experiments and
performance of the illumination light source was routinely mon-
itored using appropriate light dosimetry. Regions (200 × 200 m)
outside the sample were determined as background and detector
was set to minimize the effect of background and auto ﬂuorescence.
No upper margin or cut-off was  selected to avoid trimming of the
data. Images were loaded into ImageJ software (v. 1.47; NIH, USA)
and a line perpendicular to the basal membrane was  drawn through
the epidermis. Pixel intensities along this line were recorded and
allocated to their distance from basal membrane. Data was grouped
into depth categories of 5 m width (e.g., 0–5 m;  5–10 m etc.)
and median values and median absolute deviation (MAD) were
calculated category-wise.
2.6. PpIX extraction and analysis
For the microﬂuorimetric quantiﬁcation of PpIX, ten 20 m
tissue sections from the same eyelid were transferred to a reac-
tion tube and treated with a two-step lysis and PpIX extraction
buffer combination as and PpIX was  quantiﬁed using a ﬂuores-
cence microplate reader (Mithras LB 940, Berthold) as previously
described [5,7]. Measurement values of a lysis/extraction buffer
mixture served as blanks and were subtracted from all values. Raw
data was converted to PpIX concentrations in lysate by using refer-
ence samples. Median values and median absolute deviations were
calculated for all time points and treatment conditions.
2.7. Data processing and statistics
Data are expressed as medians. As a measure of variation,
median absolute deviation was  chosen. For statistical testing, Win-
STAT for Microsoft Excel (v. 2007.1) and SigmaStat (v. 3.5) software
were used. For comparison of two  groups, the Mann–Whitney
U-test was used, for multiple comparisons, Kruskal–Wallis ANOVA-
on-ranks and Dunn’s post-hoc tests were applied. Signiﬁcance
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Table  1
Patient demographics.
Patient no. Age [years] Gender Fitzpatrick skin type Samples taken Treatment Epidermal thickness [m] Stratum corneum thickness [m]
#1 58 m II 2 Placebo/BF-200 ALA 61.8 19.5
#2  63 f II 2 Placebo/BF-200 ALA 54.8 24.4
#3  56 f II 2 Placebo/BF-200 ALA 65.2 16.8
#4  46 f II 1 BF-200 ALA 54.0 23.9
#5  40 f I 2 BF-200 ALA/20% ALA cream 33.8 18.9
#6  60 f II 2 BF-200 ALA/20% ALA cream 58.2 25.2
#7  59 m II 2 BF-200 ALA/20% ALA cream 63.6 23.2
#8  50 f II 2 BF-200 ALA/20% ALA cream 39.0 15.5
#9  47 f II 1 20% ALA cream 35.0 14.8
#10  53 f II 2 BF-200 ALA/20% ALA cream 31.0 15.7
F in du



















cig. 1. a–d Set up of the skin culture model. (a) Localization of the upper eyelid sk
urgery.  (c) 4 mm diameter punch biopsy samples in culture chamber with test item
riteria for rejection of the null hypothesis were at p ≤ 0.05. All eval-
ations on microscopic pictures were performed using ImageJ (v.
.47, NIH, USA) without prior alterations of any image parameter.
. Results
.1. Patient data and demographics
A summary of patient disposition is presented in Table 1. The
edian age of the ten patients was 53 (40–63) years, skin of eight
emale and two male patients was analysed. Except for one patient
ith Fitzpatrick skin type I, the skin type of all patients was  type II.
hickness of the vital layers of the epidermis (stratum basale to stra-
um granulosum) reached from 31 to 65 m (mean: 50 ± 13 m),
hile stratum corneum thickness varied between 14.8–25.2 m
mean: 20 ± 4 m).
.2. Microscopic evaluation of PpIX formation and intensity plots
Fig. 2 displays representative microscopic pictures of neigh-
oring cryosections subjected to either H&E staining or PpIX-
uorescence analysis. Cytoarchitecture was retained during the
ulturing process and no signs of epidermal cellular atrophy
ecame apparent in the H&E staining. Fluorescence pictures
evealed that the induction of PpIX-ﬂuorescence by both 5-ALA-
ontaining test items was restricted to the epidermis. With placebo,ring blepharoplastic surgery. (b) Representative tissue samples immediately after
he epidermis. (d) Schematic drawing of the culturing chamber.
faint ﬂuorescence signals were detected only in the stratum
corneum. As exposure times and excitation intensities were held
constant over all analyzed conditions, ﬂuorescence pictures taken
after 12 h appear nearly saturated. However, pixel intensity anal-
ysis revealed no saturation kinetics even in these pictures. No
subepidermal PpIX-formation was  detectable.
Fig. 3a–d depicts PpIX ﬂuorescence intensities as determined
from the microscopic photographs in relation to distance from
the basal membrane. Data are presented as mean values of n = 8
(BF-200 ALA), 6 (20% ALA cream) and 3 (placebo gel) independent
experiments. Fig. 3a illustrates that after 1 h of incubation PpIX ﬂuo-
rescence was not detectable in any of the treatment conditions and
a slight and non-signiﬁcant increase was  detectable for both ALA
formulations between basal membrane and 35 m distance after
3 h (Fig. 3b). After 5 h (Fig. 3c), BF-200 ALA induced visibly increased
PpIX ﬂuorescence. After 12 h (Fig. 3d) both BF-200 ALA and the 20%
ALA cream generated strong signals. After 5 and 12 h the BF-200
ALA induced PpIX signal was signiﬁcantly different from placebo
(p < 0.05; Kruskal–Wallis ANOVA-on-ranks with Dunn’s post-hoc
test) between 15 and 65 m distance from the basal membrane
(5 h) and between basal membrane itself and 55 m distance (12 h)
in the pairwise comparison (Fig. 3). As an additional read-out to the
distance-category-wise comparison, areas under the curve (AUCs)
were calculated (Fig. 4a) by integrating over the intensity plots
shown in Fig. 3. The difference between the AUCs of the 20% cream
formulation and placebo could not be assessed as statistically sig-
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Fig. 2. Representative pictures of 20 m cryosections of skin explants after application of different drugs and different incubation times. The upper three rows depict H&E
staining of the sections. Epidermal areas can be recognized by the more densely packed nuclei. Sections show no signs of cell atrophy. The epidermal boundary is indicated
i o row









tn  the ﬂuorescence pictures (lower three rows) by dashed gray lines. The lower tw
00  nm (long pass) emission illumination. PpIX-ﬂuorescence intensity is dependent
n  all pictures represent 100 m.  (For interpretation of the references to color in th
iﬁcant in this test. BF-200 ALA induced statistically superior values
f PpIX ﬂuorescence compared to placebo after 5 and 12 h (p < 0.05,
ann–Whitney U-test). No statistically signiﬁcant difference could
e found between BF-200 ALA and the cream formulation using this
ead-out, although PpIX ﬂuorescence was stronger with BF-200 ALA
han with the 20% cream formulation over almost the entire epi-
ermis. The difference seemed not reach statistical signiﬁcance due
o the poor precision of quantiﬁcation with this method.s are grayscale pictures of PpIX-ﬂuorescence derived from 400 nm excitation and
st sample and incubation time and appears exclusively in the epidermis. Scale bars
re legend, the reader is referred to the web version of this article.)
3.3. PpIX concentration in skin tissue lysates
To devise a more quantitative approach to measure PpIX levels
in the epidermis we  measured PpIX concentrations in lysates of the
sections neighboring those analyzed microscopically (Fig. 4a). Only
samples treated with BF-200 ALA or 20% ALA cream were subjected
to this analysis, as PpIX induction had been absent microscopically
in the placebo group. Using BF-200 ALA, median PpIX concentra-
tions increased to 2.6 nmol/l after 1 h, 7.1 and 8.8 nmol/l after 3
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Fig. 3. Spatial distribution of PpIX in the epidermis. PpIX-ﬂuorescence was  quantiﬁed from microscopic pictures and plotted against the distance from the basal-membrane.
a–d  show the spatially stratiﬁed signal intensities for BF-200 ALA (red line), 20% 5-ALA cream (green line) and placebo gel (blue line) after 1, 3, 5 and 12 h, respectively. Data
are  expressed as median values of n = 8 (BF-200 ALA), n = 3 (Placebo gel) and n = 6 (20% 5-ALA cream) independent experiments with skin material from 10 different patients.
Error  bars depict median absolute deviation (MAD). Data points were tested for statistical signiﬁcance using Kruskal–Wallis ANOVA-on-ranks with Dunn’s post-hoc test.
*p < 0.05, (BF = BF-200 ALA; Pl = Placebo). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 4. (a) Area under curve (AUC) calculations from the microscopically assessed ﬂuorescence values. PpIX ﬂuorescence over the whole measurement area was  calculated
as  AUC for the three treatment groups. Data points represent median values (BF-200 ALA (n = 8), 20% ALA cream (n = 6), placebo (n = 3)). Error bars represent median absolute
deviation (MAD). *p < 0.05 (Kruskal–Wallis ANOVA-on-ranks with Dunn’s post-hoc test). (b) PpIX quantiﬁcation in tissue lysates. PpIX was  extracted from 200 [10 × 20] m
of  tissue treated with the two ALA containing drugs (BF-200 ALA, solid line; 20% ALA cream, dashed line, respectively), measured ﬂuorimetrically and plotted against the
incubation times. Fluorescence values were converted to nmol/l PpIX using PpIX reference values measured in parallel to the test samples. Data points show median values
of  n = 8 (BF-200 ALA) and n = 7 (20% ALA cream) independent experiments with eyelids from 10 different patients. Error bars represent median absolute deviation (MAD).
*p < 0.05 (Mann–Whitney U-test); **p < 0.01 (Mann–Whitney U-test).
Table 2
PpIX concentrations in tissue lysates (median ± MAD).
Treatment Incubation time
0 h 1 h 3 h 5 h 12 h
PpIX concentration
[nmol/l]
BF-200 ALA 0.0 ± 0.0 2.6 ± 2.3 7.1 ± 5.5 8.8 ± 3.0 30.0 ± 4.6
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nd 5 h, respectively and further to 30.0 nmol/l after 12 h (Table 2).
ith the 20% 5-ALA cream, PpIX concentrations also increased with
ime, albeit slower. With this preparation, concentrations were
.3 nmol/l after 1 h, 1.9 and 1.6 nmol/l after 3 and 5 h, respectively
nd 6.7 nmol/l after 12 h of incubation (Table 2). PpIX induction
ccurred earlier with BF-200 ALA than with the 20% ALA formula-
ion and was signiﬁcantly higher at time points from 3 h (p < 0.05
fter 3 and 5 h, and p < 0.01 after 12 h, respectively, applying the
ann–Whitney U-test).
. Discussion
The most relevant parameter determining efﬁcacy and sus-
ained disease control in topical PDT of non-melanoma skin cancers
s the penetration depth of the photosensitizer. This correlation
as conﬁrmed in a recent phase III clinical trial in which BF-200
LA was compared to a commercial methyl-ALA (MAL) preparation
n the treatment of actinic keratosis (AK) while penetration depth
nd ﬂuorescence intensity were analyzed in a porcine skin model.
F-200 ALA achieved higher clearance rates and better long-term
isease control and also triggered higher penetration depth and
pIX ﬂuorescence intensity in the porcine skin model [10,18,19].
s actinic keratosis is due to the presence of mutated keratinocytes
t the basal layer of the epidermis [1] in which mitosis occurs, deep
enetration seems mandatory for long-term clearance. The concept
f ﬁeld cancerization postulates the existence of subclinical lesions
20] with neoplastic keratinocyte stem cells existing in the basal
ayer long before AK becomes clinically visible. This is conﬁrmed
y observations that even low-grade actinic keratosis can trans-
orm to squamous cell carcinoma (SCC) without ﬁrst progressing
hrough the clinically more advanced stages of AK [21–23].
The current study was designed to compare two formulations
f ALA currently used in clinical practice, the BF-200 ALA 10% for-
ulation with nanoemulsion approved as Ameluz® and a 20% ALA
ream formulation in a standard ointment (nonionic hydrophilic
ream NRF). 20% ALA cream as prepared by compounding pharma-
ies is one of the most frequently used none approved formulation
or PDT [24,25]. To avoid criticism that may  derive from the use
f porcine skin [10] we designed an in vitro tissue culture model
sing human facial skin to test PpIX formation. For clinical impli-
ations, i.e., higher efﬁcacy, it was of strong interest to determine
hether a difference in PpIX formation between BF-200 ALA and
he 20% formulation can be found. Limitations of the study were
he small number of patients and a low median age of 53 years in
ur population.
Nanoemulsion formulations of soluble lipid vesicles offer advan-
ages for topical drug application [8]. The nature of the interaction
f the drug with nanovesicles depends on the lipophilic proper-
ies of the drug. BF-200 is an oil-in-water nanoemulsion containing
hosphatidylcholine-coated lipid vesicles of a nanometer scale
10]. ALA is a polar and zwitterionic hydrophilic molecule [3], prone
o head-to-head condensation in aqueous solutions [26]. Com-
ining it with the nanoemulsion increased stability of ALA to 36
onths. The nonionic hydrophilic cream used in standard formu-
ations is a pharmaceutically relevant comparator, as it is, in spite
f an approval, clinically used as pharmacy compounding product.
t also represents an oil-in-water emulsion, albeit with a markedly
igher vesicle size, providing ALA stability for few days only [4].
s outlined above, epidermal penetration may, in the absence of a
ide-by-side comparison in clinical studies, serve as an indicator of
linical efﬁcacy.The design of our test system was inspired by Lebonvallet et al.
27] who described a “Trowell-type organ culture chamber” for skin
xplants, that mimics a physiological environment and allows sur-
ival of the explants for several days [27]. Using this technique,dynamic Therapy 14 (2016) 40–46 45
we found the skin explants well-preserved and without signs of
atrophy.
Upper eyelids seem well suited because of their rather invariant
thickness of both vital and corniﬁed epidermal layers. As observed
earlier [28], at an age span from 50 to 70 years thickness of facial epi-
dermis is constant around 50 m.  Since stratum corneum hinders
drug penetration low variability is important [9]. Stratum corneum
thickness was  rather invariant between samples in our experi-
ments, and no correlation was  found between stratum corneum
thickness and PpIX formation. Thickness of the vital epidermal
layers was found to be 50 ± 13 m.  Moreover, PpIX formation in
human skin declines with age [29]. Our study population with a
median age of 53 (40–63) years differs from usual elderly patients
suffering from actinic keratosis. However, we  assume that the cen-
tral ﬁndings can be transferred to the elderly as well, even if the
absolute values may decline equally for both treatments. In terms
of consistency of the data, it is rather an advantage to have patients
from a more homogeneous age group, as this may reduce the impact
of age on the data within the treatment arms. In consideration of
a possible photo damage of the human facial skin we  choose the
upper eyelid skin, which should carry as little UV damage as pos-
sible. Furthermore, two  samples (left and right eyelid) were taken
per patient in 8 out of 10 cases. These two  samples were randomly
allocated to different treatment regimes in a side by side experi-
mental setting. This should greatly aid to reduce the impact of inter
individual differences.
PpIX formation was  greatly superior after application of the
nanoemulsion gel compared to the cream formulation, in spite
of the 2-fold higher ALA concentration. This was  ﬁrst indicated
by quantiﬁcation from microscopic pictures the quantiﬁcation
of which was, however, hampered by large standard deviations
caused by slice quality, background and saturation effects of the
CCD camera [30]. To overcome this problem we established a par-
allel biochemical PpIX read-out to provide quantitative results
beyond the microscopical ﬁndings on spatial ﬂuorescence distri-
bution. Fluorimeter measurements were performed on the same
tissue samples, using slices immediately adjacent to those analyzed
by microscopy. At all analyzed time points, PpIX concentrations
were 2-fold up to almost 5-fold higher with BF-200 ALA than with
the 20% ALA cream. The difference was statistically signiﬁcant after
3, 5 and 12 h, in full agreement with the visual appearance on the
microscopic results.
Using the ﬂuorimetric measurements, the difference between
the two  preparations was signiﬁcant already at the clinically rel-
evant time point of 3 h, at which the microscopic analysis did not
reveal increased PpIX ﬂuorescence at all. This illustrates the lower
sensitivity and the lower limit of quantiﬁcation of the microscopic
readout.
Other authors also concluded that hydrophilic creams are poor
5-ALA vehicles when comparing different ALA formulations [9],
among them also ALA in hydrophilic ointment. Even after 24 h the
ALA ointment did not trigger PpIX formation at the basal membrane
in porcine skin. In our study, the 20% cream formulation did reach
the basal membrane but the ﬂuorescence increase was not statis-
tically signiﬁcant. The most efﬁcient formulation in [11] was ALA
in an alcohol/HCl liquid vehicle, which induced PpIX distribution
throughout the epidermis after 24 h. Even though this formulation
was never directly compared with the ALA nanoemulsion, the latter
was analyzed in the same porcine skin model, albeit using different
time points [9]. Therefore, only an indirect comparison is possible,
indicating a similar penetration efﬁcacy after 3–5 h. It will be of
interest to compare these two ALA-drugs in our model. Another
study assessed the impact of ablative laser pretreatment on the
PpIX formation from ALA cream and solution in an ex vivo porcine
skin model. Authors could demonstrate that low-dose continu-
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peed and intensity of PpIX formation. Such pretreatment modali-
ies would be most interesting to analyze in this human skin model
n future studies [31].
In summary, we analyzed PpIX distribution microscopically in a
uman facial skin epidermal model that may  be closer to the clinical
ituation than previous work with porcine skin and additionally
rovides the opportunity to analyze diseased skin in future studies.
e furthermore precisely quantiﬁed PpIX after various times of
ncubation using tissue lysates. The comparison between a 20% ALA
ream and a 10% ALA nanoemulsion gel, two clinically used ALA
ormulations, indicated that the nanoemulsion gel triggered about
 to 5 times higher PpIX formation in the epidermis. Based on these
esults, it may  be speculated that the nanoemulsion will yield a
etter clinical outcome than standard creams.
onsent
Informed consent was obtained from all individual participants
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